The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle
Open accessAbstract
Background —Although percutaneous transluminal coronary angioplasty (PTCA) is a highly effective procedure to reduce the severity of stenotic coronary atherosclerotic disease, its long-term success is significantly limited by the high rate of restenosis. Several cellular and molecular mechanisms have been implicated in the development of restenosis post-PTCA, including vascular smooth muscle cell (VSMC) activation, migration, and proliferation. Recently, our group demonstrated that rapamycin, an immunosuppressant agent with antiproliferative properties, inhibits both rat and human VSMC proliferation and migration in vitro. In the present study, we investigated (1) whether rapamycin administration could reduce neointimal thickening in a porcine model of restenosis post-PTCA and (2) the mechanism by which rapamycin inhibits VSMCs in vivo. Methods and Results —PTCA was performed on a porcine model at a balloon/vessel ratio of 1.7±0.2. Coronary arteries were analyzed for neointimal formation 4 weeks after PTCA. Intramuscular administration of rapamycin started 3 days before PTCA at a dose of 0.5 mg/kg and continued for 14 days at a dose of 0.25 mg/kg. Cyclin-dependent kinase inhibitor (CDKI) p27 kip1 protein levels and pRb phosphorylation within the vessel wall were determined by immunoblot analysis. PTCA in the control group was associated with the development of significant luminal stenosis 4 weeks after the coronary intervention. Luminal narrowing was a consequence of significant neointimal formation in the injured areas. Rapamycin administration was associated with a significant inhibition in coronary stenosis (63±3.4% versus 36±4.5%; P <0.001), resulting in a concomitant increase in luminal area (1.74±0.1 mm 2 versus 3.3±0.4 mm 2 ; P <0.001) after PTCA. Inhibition of proliferation was associated with markedly increased concentrations of the p27 kip1 levels and inhibition of pRb phosphorylation within the vessel wall. Conclusions —Rapamycin administration significantly reduced the arterial proliferative response after PTCA in the pig by increasing the level of the CDKI p27 kip1 and inhibition of the pRb phosphorylation within the vessel wall. Therefore, pharmacological interventions that elevate CDKI in the vessel wall and target cyclin-dependent kinase activity may have a therapeutic role in the treatment of restenosis after angioplasty in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands
Schreiber, S. L. (1991) · Science · doi:10.1126/science.1702904 · Cited by 1,494
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Chen, P.-L., Scully, P., Shew, J.-Y., Wang, J. Y. J., & Lee, W.-H. (1989) · Cell · doi:10.1016/0092-8674(89)90517-5 · Cited by 952
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., & Rosenberg, R. D. (1992) · Nature · doi:10.1038/359067a0 · Cited by 731
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.
Cordon‐Cardo, C. (1995) · PubMed · Cited by 607
Cited by
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Morice, M.-C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,033
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
INFLAMMATION AND ATHEROSCLEROSIS
Hansson, G. K., Robertson, A.-K. L., & Söderberg-Nauclér, C. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100100 · Cited by 1,046
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies
Dzau, V. J., Braun-Dullaeus, R. C., & Sedding, D. G. (2002) · Nature Medicine · doi:10.1038/nm1102-1249 · Cited by 831
Sousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I. M. F., Seixas, A. C., Staico, R., Mattos, L. A., Sousa, A. G. M. R., et al. (2001) · Circulation · doi:10.1161/01.cir.103.2.192 · Cited by 793
Sirolimus: its discovery, biological properties, and mechanism of action
Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 779
Serruys, P. W., Kutryk, M. J. B., & Ong, A. T. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmra051091 · Cited by 762
Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model
Suzuki, T., Kopia, G., Hayashi, S.-I., Bailey, L. R., Llanos, G., Wilensky, R., Klugherz, B. D., Papandreou, G., Narayan, P., Leon, M. B., et al. (2001) · Circulation · doi:10.1161/hc3601.093987 · Cited by 708
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint
Roy-Chaudhury, P., Sukhatme, V. P., & Cheung, A. K. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050615 · Cited by 584
Schampaert, E., Cohen, E. A., Schlüter, M., Reeves, F., Traboulsi, M., Title, L. M., Kuntz, R. E., & Popma, J. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.01.024 · Cited by 575
Molecular Basis of Restenosis and Drug-Eluting Stents
Costa, M. A., & Simon, D. I. (2005) · Circulation · doi:10.1161/01.cir.0000163587.36485.a7 · Cited by 510
Garg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis
Marx, S. O., & Marks, A. R. (2001) · Circulation · doi:10.1161/01.cir.104.8.852 · Cited by 447
Self-citationDuda, S. H., Pusich, B., Richter, G., Landwehr, P., Oliva, V. L., Tielbeek, A., Wiesinger, B., Hak, J. B., Tielemans, H., Ziemer, G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000029746.10018.36 · Cited by 446
Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy
Mancini, D., Pinney, S., Burkhoff, D., LaManca, J., Itescu, S., Burke, E., Edwards, N., Oz, M., & Marks, A. R. (2003) · Circulation · doi:10.1161/01.cir.0000070421.38604.2b · Cited by 442
Self-citationCoronary in-stent restenosis: Current status and future strategies
Lowe, H. C., Oesterle, S. N., & Khachigian, L. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01742-9 · Cited by 414
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Vascular Smooth Muscle Cell Proliferation in Restenosis
Marx, S. O., Totary-Jain, H., & Marks, A. R. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.957332 · Cited by 354
Self-citationMorrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m100392-jlr200 · Cited by 295
CARTER, A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.04.029 · Cited by 281
Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc
Yang, W., Shen, J., Wu, M., Arsura, M., FitzGerald, M., Suldan, Z., Kim, D. W., Hofmann, C. S., Pianetti, S., Romieu-Mourez, R., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204245 · Cited by 277
AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game
Canaud, G., Legendre, C., & Terzi, F. (2015) · Lupus · doi:10.1177/0961203315569336 · Cited by 32
Metadata
- Authors
- Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., & Badimon, J. J.
- Venue
- Circulation
- Published
- 1999-04-27
- Volume
- 99
- Issue
- 16
- Pages
- 2164-2170
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1974046965
- Cited by
- 490
- References
- 32
- FWCI
- 26.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.